Arena Pharma (ARNA) Reports First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areata
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that the first subject has been dosed in a Phase 2 trial evaluating etrasimod, an investigational, next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator, for the potential treatment of moderate-to-severe alopecia areata. The randomized, placebo-controlled trial will evaluate the efficacy and safety of etrasimod 2 mg for 24 weeks in 36 subjects in sites across the United States and Canada.
"It is exciting to see the clinical advancement of an oral agent with a novel mechanism of action for the potential treatment of alopecia areata," stated Brett King, MD, PhD, Associate Professor of Dermatology, Yale School of Medicine. "With no currently FDA-approved treatment options there is a significant unmet medical need in alopecia areata. I see patients suffer tremendous emotional and psychosocial distress and reduced quality of life as a result of this disease. I look forward to seeing the progress of Arena's Phase 2 program and the development of etrasimod."
"Dosing the first patient in our Phase 2 alopecia areata trial is a great accomplishment for the team, furthering our expansion into dermatology," stated Chris Cabell, MD, MHS, FACC, Executive Vice President, Head of Research and Development, and Chief Medical Officer at Arena. "To date, we have seen preclinical and scientific validation supporting the rationale for moving etrasimod into alopecia areata and other dermatologic conditions. Etrasimod has demonstrated the potential to reduce circulating CD4+ and CD8+ T-lymphocytes. In alopecia areata, this may reduce the T cells available to infiltrate the hair follicle, which may decrease inflammation and restore hair growth. We expect the availability of Phase 2 data in 2021."
This Phase 2 multicenter, randomized, placebo-controlled trial will assess the safety and efficacy of once-daily etrasimod 2 mg in subjects with moderate-to-severe alopecia areata. The primary endpoint is percent change in Severity of Alopecia Tool (SALT) score from baseline to week 24. The trial will enroll 36 subjects and will be conducted in study sites across the United States and Canada.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apollo Global Management (APO) to Buy US Silica (SLCA) for $15.50/sh Cash
- Apellis' (APLS) Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by EMA
- AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints
Create E-mail Alert Related Categories
Corporate News, FDA, Management CommentsRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!